Structural basis for CCR6 modulation by allosteric antagonists
The CC chemokine receptor 6 (CCR6) is a potential target for chronic inflammatory diseases. Previously, we reported an active CCR6 structure in complex with its cognate chemokine CCL20, revealing the molecular basis of CCR6 activation. Here, we present two inactive CCR6 structures in ternary complexes with different allosteric antagonists, CCR6/SQA1/OXM1 and CCR6/SQA1/OXM2. The oxomorpholine analogues, OXM1 and OXM2 are highly selective CCR6 antagonists which bind to an extracellular pocket and disrupt the receptor activation network. An energetically favoured U-shaped conformation in solution that resembles the bound form is observed for the active analogues. SQA1 is a squaramide derivative with close-in analogues reported as antagonists of chemokine receptors including CCR6. SQA1 binds to an intracellular pocket which overlaps with the G protein site, stabilizing a closed pocket that is a hallmark of inactive GPCRs. Minimal communication between the two allosteric pockets is observed, in contrast to the prevalent allosteric cooperativity model of GPCRs. This work highlights the versatility of GPCR antagonism by small molecules, complementing previous knowledge of CCR6 activation, and sheds light on drug discovery targeting CCR6.
Authors
- Ru Ding (ORCID: https://orcid.org/0000-0002-4214-100X)
- Kathleen A. Farley (ORCID: https://orcid.org/0000-0001-8935-6852)
- Fabien Vincent (ORCID: https://orcid.org/0000-0002-8782-0225)
- Atli Thorarensen (ORCID: https://orcid.org/0000-0002-6791-5809)
- Jennifer Alley
- Elena Segala (ORCID: https://orcid.org/0000-0001-7878-8633)
- Gabriel Berstein (ORCID: https://orcid.org/0000-0001-7610-6782)
- Roger Cooke (ORCID: https://orcid.org/0000-0003-0643-1971)
- Philippe Nuhant (ORCID: https://orcid.org/0000-0001-7816-7474)
- Ray Unwalla (ORCID: https://orcid.org/0000-0002-5789-7336)
- James J. Mousseau (ORCID: https://orcid.org/0000-0002-5712-9222)
- Mark E. Schnute (ORCID: https://orcid.org/0000-0003-3075-4578)
- John I. Trujillo (ORCID: https://orcid.org/0000-0003-2303-0256)
- Chulho Choi (ORCID: https://orcid.org/0000-0003-3459-3767)
- Seungil Han (ORCID: https://orcid.org/0000-0002-1070-3880)
- Parag V. Sahasrabudhe (ORCID: https://orcid.org/0000-0002-8442-637X)
- Prolay K. Mondal
- Kimberly Crouse
- Huixian Wu (ORCID: https://orcid.org/0000-0003-1357-9747)
- Richard K. Frisbie
- Brian S. Gerstenberger (ORCID: https://orcid.org/0000-0002-6553-1975)
- Mathieu Rappas (ORCID: https://orcid.org/0000-0002-6852-9520)
- Daniel Lamb
- G.S. Minhas (ORCID: https://orcid.org/0000-0003-4320-1243)
- Ian W. Windsor (ORCID: https://orcid.org/0000-0002-6289-6928)
- Gary M. Chinigo (ORCID: https://orcid.org/0009-0009-6130-6808)
- Matthew F. Calabrese (ORCID: https://orcid.org/0000-0002-9394-3686)
- Christine Oswald
- Alpay Dermenci
- Vincent M. Lombardo
- Jorge Victorino (ORCID: https://orcid.org/0000-0003-3331-4340)
- Andrew C. Flick (ORCID: https://orcid.org/0000-0003-2822-0104)
- Wěi Li (ORCID: https://orcid.org/0000-0002-9522-4474)
- Barbara J. Hogan
- David Jonathan Wasilko
Institutions
- Pfizer (United States) (US)
- Granta Design (United Kingdom) (GB)
- Heptares Therapeutics (United Kingdom) (GB)
Publication Details
- Journal
- Nature Communications
- Published
- 2024-08-31
- DOI
- https://doi.org/10.1038/s41467-024-52045-7
- Citations
- 17
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 6.87
Funders
- Pfizer